Join
Live feed
·
PRReleasevia Quantisnow
InflaRx N.V. logo

InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum

ByQuantisnow·Wall Street's wire, on your screen.
IFRX· InflaRx N.V.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IFRX (InflaRx N.V.) and more on Quantisnow.